药学视角下的聚腺苷二磷酸核糖聚合酶抑制剂在卵巢癌中的应用进展  

Advances of clinical application of PARP inhibitors in ovarian cancer from pharmaceutical perspectives

作　　者：王燕婷 戴媛媛 孙阳春 李国辉 WANG Yan-ting;DAI Yuan-yuan;SUN Yang-chun;LI Guo-hui(Department of Pharmacy,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Gynecologic Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心,国家肿瘤临床医学研究中心,中国医学科学院北京协和医学院肿瘤医院药剂科,北京100021 [2]国家癌症中心,国家肿瘤临床医学研究中心,中国医学科学院北京协和医学院肿瘤医院妇瘤科,北京100021

出　　处：《中国新药杂志》2021年第13期1200-1206,共7页Chinese Journal of New Drugs

基　　金：中国医学科学院中央级公益性科研院所基本科研业务费临床与转化医学研究基金资助项目(2019XK320066);中国癌症基金会北京希望马拉松专项基金青年课题(LC2018B09)。

摘　　要：聚腺苷二磷酸核糖聚合酶(poly ADP-ribose polymerase,PARP)抑制剂是靶向PARP酶的抗肿瘤药物,已经被美国FDA批准用于卵巢癌、乳腺癌、前列腺癌、胰腺癌的治疗;在我国也被国家药品监督管理局(NMPA)批准用于卵巢癌的治疗。PARP抑制剂在卵巢中的获批,改变了卵巢癌的传统治疗模式。本文从PARP抑制剂的作用机制、获批适应证、药动学特点、临床应用、药学服务关键点等方面对该类药物进行综述,为其合理使用及药学服务提供参考。Poly ADP ribose polymerase(PARP)inhibitors are anti-tumor drugs targeting PARP enzymes.They have been approved by the US Food and Drug Administration(FDA)for the treatment of ovarian cancer,breast cancer,prostate cancer and pancreatic cancer.Additionally,National Medical Products Administration of China has also approved them for ovarian cancer.So far,PARP inhibitors have changed the traditional treatment mode for ovarian cancer.This article conducts literature review for PARP inhibitors in aspects of mechanisms of action,indications,pharmacokinetics,clinical application,and key points for pharmaceutical care,so as to provide reference to clinicians for rational use in clinical and pharmacy service for PARP inhibitors.

关 键 词：PARP抑制剂 卵巢癌 作用机制 药动学 临床应用 药学服务 

分 类 号：R972.6[医药卫生—药品]